319 related articles for article (PubMed ID: 25202923)
21. Emtricitabine/tenofovir disoproxil fumarate.
Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
[TBL] [Abstract][Full Text] [Related]
22. Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.
Radzio J; Henning T; Jenkins L; Ellis S; Farshy C; Phillips C; Holder A; Kuklenyik S; Dinh C; Hanson D; McNicholl J; Heneine W; Papp J; Kersh EN; García-Lerma JG
J Infect Dis; 2016 May; 213(10):1541-5. PubMed ID: 26743846
[TBL] [Abstract][Full Text] [Related]
23. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Zolopa A; Sax PE; DeJesus E; Mills A; Cohen C; Wohl D; Gallant JE; Liu HC; Plummer A; White KL; Cheng AK; Rhee MS; Szwarcberg J;
J Acquir Immune Defic Syndr; 2013 May; 63(1):96-100. PubMed ID: 23392460
[TBL] [Abstract][Full Text] [Related]
24. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
Donnell D; Baeten JM; Bumpus NN; Brantley J; Bangsberg DR; Haberer JE; Mujugira A; Mugo N; Ndase P; Hendrix C; Celum C
J Acquir Immune Defic Syndr; 2014 Jul; 66(3):340-8. PubMed ID: 24784763
[TBL] [Abstract][Full Text] [Related]
25. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Lyseng-Williamson KA; Scott LJ
Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088
[TBL] [Abstract][Full Text] [Related]
26. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
[TBL] [Abstract][Full Text] [Related]
27. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
Okwundu CI; Uthman OA; Okoromah CA
Cochrane Database Syst Rev; 2012 Jul; (7):CD007189. PubMed ID: 22786505
[TBL] [Abstract][Full Text] [Related]
28. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
29. Preexposure prophylaxis for HIV prevention: where have we been and where are we going?
Baeten JM; Haberer JE; Liu AY; Sista N
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S122-9. PubMed ID: 23764623
[TBL] [Abstract][Full Text] [Related]
30. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions.
Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624
[TBL] [Abstract][Full Text] [Related]
31. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
[TBL] [Abstract][Full Text] [Related]
32. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial.
Cahn P; Sax PE; Squires K; Molina JM; Ratanasuwan W; Rassool M; Bloch M; Xu X; Zhou Y; Homony B; Hepler D; Teppler H; Hanna GJ; Nguyen BY; Greaves W;
J Acquir Immune Defic Syndr; 2018 Aug; 78(5):589-598. PubMed ID: 29771789
[TBL] [Abstract][Full Text] [Related]
33. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
34. Delayed maturation of antibody avidity but not seroconversion in rhesus macaques infected with simian HIV during oral pre-exposure prophylaxis.
Curtis KA; Kennedy MS; Luckay A; Cong ME; Youngpairoj AS; Zheng Q; Smith J; Hanson D; Heneine W; Owen SM; García-Lerma JG
J Acquir Immune Defic Syndr; 2011 Aug; 57(5):355-62. PubMed ID: 21637113
[TBL] [Abstract][Full Text] [Related]
35. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.
Parikh UM; Dobard C; Sharma S; Cong ME; Jia H; Martin A; Pau CP; Hanson DL; Guenthner P; Smith J; Kersh E; Garcia-Lerma JG; Novembre FJ; Otten R; Folks T; Heneine W
J Virol; 2009 Oct; 83(20):10358-65. PubMed ID: 19656878
[TBL] [Abstract][Full Text] [Related]
36. A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk.
Butler K; Ritter JM; Ellis S; Morris MR; Hanson DL; McNicholl JM; Kersh EN
J Acquir Immune Defic Syndr; 2016 Aug; 72(4):363-71. PubMed ID: 27355414
[TBL] [Abstract][Full Text] [Related]
37. Interaction of Depot Medroxyprogesterone Acetate and Tenofovir Disoproxil Fumarate/Emtricitabine on Peripheral Blood Mononuclear Cells and Cervical Tissue Susceptibility to HIV Infection and Pharmacokinetics.
Coleman JS; Diniz CP; Fuchs EJ; Marzinke MA; Aung W; Bakshi RP; Farzadegan H; Bream JH; Nilles TL; Hudson S; Bumpus NN; Schwartz GJ; Rosenblum MA; Rooney JF; Hendrix CW
J Acquir Immune Defic Syndr; 2023 Jan; 92(1):89-96. PubMed ID: 36305827
[TBL] [Abstract][Full Text] [Related]
38. Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.
Tsegaye TS; Butler K; Luo W; Radzio J; Srinivasan P; Sharma S; Aubert RD; Hanson DL; Dobard C; Garcia-Lerma JG; Heneine W; McNicholl JM; Kersh EN
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):385-94. PubMed ID: 25886925
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women.
Grant RM; Liegler T; Defechereux P; Kashuba AD; Taylor D; Abdel-Mohsen M; Deese J; Fransen K; De Baetselier I; Crucitti T; Bentley G; Agingu W; Ahmed K; Damme LV
AIDS; 2015 Jan; 29(3):331-7. PubMed ID: 25503265
[TBL] [Abstract][Full Text] [Related]
40. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
